November 18, 2014

On November 18, 2014, Novo Nordisk A/S agreed to pay $19 million to settle a putative class action accusing it of attempting to monopolize the market for popular diabetes treatment Prandin by pursuing sham infringement litigation against generic-drug makers.

The suit, which was filed in May 2010, claimed that Novo Nordisk has maintained an unlawful monopoly on the market for repaglinide — sold under the brand name Prandin in the U.S. — by blocking generic versions of the drug from the market though fraudulent Orange Book filings and sham patent infringement cases.

Cohen Milstein helped represent the plaintiffs in this case, In re: Prandin Direct Purchaser Antitrust Litigation, case number 2:10-cv-12141, in the U.S. District Court for the Eastern District of Michigan.